GANC抗体;GANC Antibody—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: TM4 cell lysate, Primary antibody: P13444(GANC Antibody) at dilution 1/550, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P13444(GANC Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P13444(GANC Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

GANC antibodies, targeting ganciclovir, are immune responses that may develop in patients undergoing long-term ganciclovir therapy, particularly in immunocompromised individuals such as transplant recipients or those with HIV/AIDS. Ganciclovir, a nucleoside analog, is widely used to treat cytomegalovirus (CMV) infections. However, prolonged exposure can trigger the production of anti-drug antibodies (ADAs), including GANC antibodies, through adaptive immune activation. These antibodies may neutralize the drug, reducing its bioavailability and therapeutic efficacy, potentially leading to treatment failure or viral resistance.

The emergence of GANC antibodies highlights challenges in managing chronic viral infections requiring extended antiviral regimens. While ADA development is less common with ganciclovir compared to biologic therapies, its clinical significance remains understudied. Risk factors include high-dose regimens, intermittent dosing, and genetic predispositions. Monitoring antibody titers and viral load is crucial in refractory CMV cases to guide therapeutic adjustments, such as switching to alternative antivirals (e.g., foscarnet or letermovir) or optimizing immunosuppression. Further research is needed to clarify the prevalence, kinetics, and clinical impact of GANC antibodies to refine personalized treatment strategies.